Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer

Clin Nucl Med. 2018 Oct;43(10):755-756. doi: 10.1097/RLU.0000000000002212.

Abstract

Radiolabeled ligands targeting prostate-specific membrane antigen (PSMA) are currently being established. Prostate-specific membrane antigen radioligand therapy with Lu-PSMA-617 is a promising treatment in metastasized castration-resistant prostate cancer with high efficacy and safety and seems to prolong progression-free survival and overall survival. We present Ga-PSMA PET/CT images during and after 2 therapy courses, including each 4 cycles of Lu-PSMA-617, and prostate-specific antigen-level history of a 77-year-old heavily pretreated patient with metastasized castration-resistant prostate cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Dipeptides / therapeutic use*
  • Disease-Free Survival
  • Heterocyclic Compounds, 1-Ring / therapeutic use*
  • Humans
  • Ligands
  • Lutetium
  • Male
  • Neoplasm Metastasis
  • Positron Emission Tomography Computed Tomography
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
  • Prostatic Neoplasms, Castration-Resistant / pathology*
  • Prostatic Neoplasms, Castration-Resistant / radiotherapy*
  • Treatment Outcome

Substances

  • 177Lu-PSMA-617
  • Dipeptides
  • Heterocyclic Compounds, 1-Ring
  • Ligands
  • Lutetium
  • Prostate-Specific Antigen